Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes
about
Metabolic profiling in Maturity-onset diabetes of the young (MODY) and young onset type 2 diabetes fails to detect robust urinary biomarkersUse of HbA1c in the identification of patients with hyperglycaemia caused by a glucokinase mutation: observational case control studiesMetrics Beyond Hemoglobin A1C in Diabetes Management: Time in Range, Hypoglycemia, and Other Parameters.Racial differences in glycemic markers: a cross-sectional analysis of community-based dataAssessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations.A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes.Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes.Comparison of two assays for serum 1,5-anhydroglucitolSystematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young.Metabolomic biomarkers for personalised glucose lowering drugs treatment in type 2 diabetes.Mutations in HNF1A result in marked alterations of plasma glycan profile1,5-Anhydroglucitol in diabetes mellitus.When is it MODY? Challenges in the Interpretation of Sequence Variants in MODY Genes.A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.Evaluation of 1,5-anhydroglucitol as a marker for glycemic variability in patients with type 2 diabetes mellitus.HDL cholesterol as a diagnostic tool for clinical differentiation of GCK-MODY from HNF1A-MODY and type 1 diabetes in children and young adults.
P2860
Q28481662-4FCDD581-A17F-42F0-8CC3-2DC47B7D10EEQ31120060-CED166C3-91C5-4E92-B309-80B9E26274AFQ33727475-789E326E-A9AC-4ABA-B44E-2224EAAA7328Q33831561-244DBEA3-CAD1-403D-832A-A59D1E659D7BQ34084456-E53E74E5-3C06-4DCB-97DF-B7EB933082F5Q34205887-646EAF55-48C8-4084-9966-21DBD76DAD83Q34507037-58AE136A-6027-4688-8907-E68B3CDC5DB6Q34594157-7555CB0A-3450-4C29-B507-1D02A2382175Q35976364-D6904CEA-7935-460E-86EA-C860FF38C22AQ36437420-C2C21664-C817-46DD-9A2C-D12E24418F2AQ36720490-6FBAF776-4805-4E87-B12F-71F31924EED8Q38030840-6107731D-2F23-4E44-9F2C-C9F9D0613258Q38816600-D0B2D802-8B1B-4A77-A1B4-E8B9DC4F5660Q41020576-6F93DD5B-27B5-4E1D-A472-A64B60A7CC62Q51371829-2FF78190-EDDB-4C37-A79B-47D68D6E88CDQ54594220-8140D0E3-E7C4-47AB-B0EF-F9288FE1B03B
P2860
Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Evaluation of serum 1,5 anhydr ...... erentiate subtypes of diabetes
@ast
Evaluation of serum 1,5 anhydr ...... erentiate subtypes of diabetes
@en
type
label
Evaluation of serum 1,5 anhydr ...... erentiate subtypes of diabetes
@ast
Evaluation of serum 1,5 anhydr ...... erentiate subtypes of diabetes
@en
prefLabel
Evaluation of serum 1,5 anhydr ...... erentiate subtypes of diabetes
@ast
Evaluation of serum 1,5 anhydr ...... erentiate subtypes of diabetes
@en
P2093
P2860
P356
P1433
P1476
Evaluation of serum 1,5 anhydr ...... erentiate subtypes of diabetes
@en
P2093
Andrew J Farmer
Aparna Pal
Beryl A Barrow
Christina Dudley
Jilly P Grew
Katharine R Owen
Mary P Selwood
Rhiannon Klyne
P2860
P304
P356
10.2337/DC09-1246
P407
P577
2009-11-23T00:00:00Z